Allergy Therapeutics Plc has received a public opening position disclosure from Cavendish Securities Plc, an exempt principal trader. The disclosure is made in accordance with Rule 8.5 of the Takeover Code. Cavendish Securities Plc is connected to Allergy Therapeutics Plc, the offeror/offeree in question. The date of the position held/dealing undertaken is 20/09/2023.

In terms of positions, Cavendish Securities Plc owns and/or controls 188,070 relevant securities of Allergy Therapeutics Plc, which represents 0.03% of the total. There are no cash-settled derivatives or stock-settled derivatives (including options) and agreements to purchase/sell.

The exempt principal trader has made purchases and sales of Allergy Therapeutics Plc's relevant securities. They have sold 219 securities at a highest price per unit of 2.58 and a lowest price per unit of 2.58. They have also bought 15,000 securities at a price per unit of 2.50.

There are no cash-settled derivative transactions, stock-settled derivative transactions, or other dealings (including subscribing for new securities) to report.

There are no indemnity or other dealing arrangements, agreements, arrangements, or understandings relating to options or derivatives to disclose.

No supplemental form for open positions is attached to the disclosure.

The disclosure was made on 21/09/2023 by Nancy Dyer, with a contact number of 0207 220 0594.

Please note that this summary only includes information directly provided in the news and excludes regulatory, contact, and general risk information.